We're seeking an experienced Principal Platform Engineer with a background architecting cloud infrastructure and driving automation excellence in an FDA-regulated environment. The Principal Platform Engineer will join a fast-paced, collaborative team implementing sophisticated CI/CD pipelines that transform how we deliver innovation to healthcare providers, while establishing infrastructure-as-code frameworks that empower our development teams. This position represents a unique opportunity to apply your DevOps skills and AWS expertise to enable the development of our cutting-edge medical-imaging SaaS solutions.
The ideal candidate will have:
- 7+ years of DevOps/SRE/Platform focused agile software engineering experience supporting containerized ECS cloud workloads on AWS using Terraform.
- Extensive hands-on experience with Linux/Ubuntu.
- Experience with infrastructure and application monitoring tools such as DataDog or NewRelic.
- Experience of building and maintaining CI/CD pipelines with GitHub actions.
- 5+ years of experience with at least one coding language, such as Bash, Ruby, Python.
- Previous experience working in FDA-regulated environments.
- Strong organization, collaboration and communication skills.
- This role has a 3:00pm EST start. Our team is hybrid and based out of our office in Boston, MA. While we prefer candidates in the Boston, MA area, we’re also accepting candidates in Central, Mountain or Pacific time zones in the continental U.S.
- Occasional travel may be required.
Similar Jobs
What We Do
Elucid is a Boston-based medical technology company using uniquely interpretable and validated AI to provide physicians with a cost-effective means to optimize treatment decisions for patients with cardiovascular disease. Advanced clinical insight from Elucid equips physicians with critical information designed to enable precision medicine. Elucid is the first FDA-Cleared and CE-marked non-invasive software to quantify atherosclerotic plaque characteristics compared to histopathology, including Lipid Rich Necrotic Core. The company has published studies for its derivation of fractional flow reserve (FFRct) based on the vasodilative capacity of the vessel wall and estimation of coding and non-coding RNA transcripts (“Virtual Transcriptomics”). This unique information informs improved treatment decisions by physicians leading to better patient outcomes, improved quality of care, and reduced healthcare costs. The Elucid software is available for commercial use in the U.S. and Europe
